Back to Search
Start Over
Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2012 May; Vol. 48 (7), pp. 990-6. Date of Electronic Publication: 2011 Dec 01. - Publication Year :
- 2012
-
Abstract
- Background: Cholangiocarcinoma (CC) is a rare cancer of the liver. Surgery offers the only chance for cure. When surgery is unfeasible, chemotherapy is the backbone of treatment. The combined administration of cisplatin and gemcitabine is considered standard of care. Human equilibrative nucleoside transporter 1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. hENT1 expression is associated with an increased survival for patients receiving gemcitabine after pancreatic cancer surgery, suggesting that hENT1 is predictive of response to gemcitabine.<br />Aim: To determine whether there is a correlation between the expression of hENT1 and disease outcome in CC.<br />Methods: A retrospective study on 43 patients treated at our centre with a locally advanced or metastatic CC, who received first line treatment with gemcitabine, was performed.<br />Results: For the whole population, median Progression Free Survival (PFS) and overall survival (OS) were 4.0 (95% Confidence Interval 2.7-5.3 months) and 10.0 months (95%CI 6.8-13.2 months), respectively. From the 26 samples available for hENT1 staining, 18 (69%) and 8 (31%) patients had high and low hENT1 immunostaining, respectively. The median PFS were 2.0 versus 6.0 months for low versus high staining respectively (p = 0.012). The median OS were 5.0 versus 11.0 months for low versus high staining, respectively (p = 0.036). On multivariate analysis, hENT1 expression was the single independent predictive factor associated with prolonged PFS (HR 0.35, p = 0.023) and OS (HR 0.41, p = 0.046).<br />Conclusion: In this study we show the potential of hENT1 expression as a predictor of outcome in CC treated with gemcitabine. Larger studies are necessary to confirm these promising results.<br /> (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic therapeutic use
Bile Duct Neoplasms mortality
Cholangiocarcinoma mortality
Deoxycytidine therapeutic use
Disease-Free Survival
Female
Humans
Male
Middle Aged
Predictive Value of Tests
Retrospective Studies
Treatment Outcome
Gemcitabine
Bile Duct Neoplasms drug therapy
Bile Duct Neoplasms metabolism
Cholangiocarcinoma drug therapy
Cholangiocarcinoma metabolism
Deoxycytidine analogs & derivatives
Equilibrative Nucleoside Transporter 1 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 48
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Academic Journal
- Accession number :
- 22137164
- Full Text :
- https://doi.org/10.1016/j.ejca.2011.11.006